Lupin debuts generic Myrbetriq
Myrbetriq is indicated for the treatment of overactive bladder.
Lupin is introducing mirabegron extended-release tablets, 25 mg, which is a generic of Astellas Pharma’s Myrbetriq.
[Read more: Lupin receives FDA OK for generic Banzel]
Myrbetriq is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency.
Mirabegron extended-release tablets, 25 mg had a market value of $1.1 billion, per IQVIA February 2024 data.